learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
5 / 801 resultslearn Folate
learn FC550
learn TDM-105795
learn Folligen Complex
Research
5 / 1000+ results
research 128 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a potent novel peptide hair growth promoter, FOL-005
FOL-005, a hair growth promoter, acts locally on mouse skin where injected and could be a promising hair loss treatment.
research 201 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a new potent novel inhibitor of human hair growth, FOL-005
Some men don't respond to common hair loss treatments, but a new inhibitor, FOL-005, shows promise for targeting unwanted hair growth.
research 695 Using MALDI-MSI analysis to study distribution of FOL-005, a potent, novel inhibitor of human hair growth, after subcutaneous injection in mice
FOL-005, a new substance, was found to reduce hair growth without toxicity when injected into skin, suggesting it could be used to treat excessive hair growth.
research An osteopontin‐derived peptide inhibits human hair growth at least in part by decreasing fibroblast growth factor‐7 production in outer root sheath keratinocytes
FOL-005 peptide can reduce human hair growth by lowering FGF7 levels.
research 129 Genetic transformation of keratoacanthoma-type cutaneous squamous cell carcinoma following intralesional chemotherapy
Intralesional chemotherapy with 5-fluorouracil and methotrexate may worsen keratoacanthoma-type skin cancer in transplant patients.
Community Join
5 / 11 resultscommunity FOL005 claims it's better than Finasteride and Minoxidil.
FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.
community Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
community When will Breezula, SM04554, Follica FOL-004, follicum FOL-005 arrive in Canada?
The conversation is about the availability of hair loss treatments Breezula, SM04554, Follica FOL-004, and Follicum FOL-005 in Canada after FDA approval, including potential delays, loopholes for obtaining them, and insurance coverage.
community Follicum releases some data from previous phase 2a trial
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
community What to look Forward to in 2025
Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.